Targaprimir-96 is a potent inhibitor of microRNA-96 (miR-96) processing. Targaprimir-96 selectively regulates the production of miR-96 in cancer/tumor cells and triggers apoptosis. Targaprimir-96 binds to primary miR-96 (pri-miR-96) with high affinity. Targaprimir-96 directly binds to pri-miR-96 in breast cancer/tumor cells and does not affect healthy breast cells.

Physicochemical Properties

Molecular Formula	C77H102N18O7
Molecular Weight	1391.78
Exact Mass	1390.817
CAS #	1655508-14-7
Related CAS #	Targaprimir-96 TFA
PubChem CID	90479856
Appearance	Typically exists as solid at room temperature
LogP	9.2
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	16
Rotatable Bond Count	33
Heavy Atom Count	102
Complexity	2630
Defined Atom Stereocenter Count	0
InChi Key	OLEDRJJUXAAJFN-UHFFFAOYSA-N
InChi Code	InChI=1S/C77H102N18O7/c1-11-28-92(69(98)20-15-39-101-58-18-13-17-52(41-58)73-80-61-24-21-53(44-64(61)83-73)74-81-62-25-22-56(45-65(62)84-74)90-35-31-88(9)32-36-90)50-70(99)93(29-12-2)51-71(100)94(49-67(78)96)47-55-48-95(87-86-55)30-16-27-79-68(97)19-14-40-102-72-59(76(3,4)5)42-54(43-60(72)77(6,7)8)75-82-63-26-23-57(46-66(63)85-75)91-37-33-89(10)34-38-91/h13,17-18,21-26,41-46,48H,11-12,14-16,19-20,27-40,47,49-51H2,1-10H3,(H2,78,96)(H,79,97)(H,80,83)(H,81,84)(H,82,85)
Chemical Name	N-[3-[4-[[(2-amino-2-oxoethyl)-[2-[[2-[4-[3-[6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenoxy]butanoyl-propylamino]acetyl]-propylamino]acetyl]amino]methyl]triazol-1-yl]propyl]-4-[2,6-ditert-butyl-4-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]phenoxy]butanamide
Synonyms	Targaprimir96; Targaprimir 96
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	By measuring the decrease in mature miR-96 levels, tartaprimir-96 demonstrated a dosage response in MDA-MB-231 triple-negative breast cancer cells, with an IC50 of roughly 50 nM. In a dose-dependent way, targaprimir-96 (50 nM) raises the amount of pri-miRNA and lowers the amounts of pre-miRNA and mature miRNA [1]. In the breast cancer cell line 4175, targaprimir-96 (50 nM; 48 hours) raises FOXO1 levels and causes apoptosis [1]. With a Kd of 85 nM, Targaprimir-96 binds RNA3, which has the Drosha site and an adjacent 1 × 1 nt GG internal loop. RNA1, RNA2, RNA4, and RNA5 bind to tartaprimir-96 with Kd values of 1.2, 0.9, 1.2, and 1.5 μM, in that order. Consequently, Targaprimir-96 exhibits high affinity and successfully distinguishes between different related targets by recognizing 1×1 nt GG and 1×1 nt UU loops, making it extremely RNA-selective [1].
ln Vivo	Targaprimir-96 (10 mg/kg; i.p.; every other day for 21 days) suppresses tumor growth in a mouse model of triple-negative breast cancer (TNBC) [1]. The amount of Targaprimir-96 (2 or 7 mg/kg; i.p.) in the plasma of FVB/n mice was approximately 4 h. Importantly, even 48 hours after injection, residual Targaprimir-96 concentrations in plasma were substantially above the 50 nM cellular value that triggers apoptosis: 1.6 μM for the 2 mg/kg dose and 1.9 μM for the 7 mg/kg dose [ 1 ].
Animal Protocol	Animal/Disease Models: Female NOD/SCID (severe combined immunodeficient) mouse (TNBC mouse model) [1] Doses: 10 mg/kg Route of Administration: intraperitoneal (ip) injection; once every other day for 21 days Experimental Results: The level of mature miR-96 diminished by approx. 50%, the levels of pri-miR-96 increased, while FOXO1 increased. No toxicity was observed.
References	[1]. Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci U S A. 2016 May 24;113(21):5898-903.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	0.7185 mL	3.5925 mL	7.1850 mL
	5 mM	0.1437 mL	0.7185 mL	1.4370 mL
	10 mM	0.0719 mL	0.3593 mL	0.7185 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.